Assessing cholinergic innervation in Parkinson*s disease using the PET imaging marker [18F]Fluoroethoxybenzovesamicol

Assessing cholinergic innervation in Parkinson*s disease using the PET imaging marker [18F]Fluoroethoxybenzovesamicol - Cholinergic PET imaging in Parkinson*s disease

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON43478

Enrollment

Registered

2016-05-24

Start date

2016-10-19

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Parkinson's disease

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Control Subjects: - Age between 45 - 65 years - Willingness to cooperate and sign written informed consent - No prior history of neurologic or psychiatric illness - Able and fit enough to participate in this study;Patient Group: - Diagnosis Parkinson*s disease - Disease duration between 3 and 10 years. - Age between 45 - 65 years - Willingness to cooperate and sign written informed consent

Exclusion criteria

Exclusion criteria: A potential subject who meets any of the following criteria will be excluded from participation in this study: - The refusal to be informed about an unforeseen clinical finding - Pregnant women, breast feeding - Exhibition to a radiation dose for other reasons (e.g. participation in other research trial), exceeding the maximum annual dose. - Anticoagulant medication, antiplatelet agents used in the 5d before the imaging visit - Contra-indication for MRI-scanning (metal parts in the body) - Other neurological conditions, more specifically neurodegenerative disorders and brain lesions. - Treatment with deep brain stimulation

Design outcomes

Primary

Measure	Time frame
The main endpoint of this study is the difference in VAChT brain binding on a [18F]FEOBV PET-scan between PD patients and healthy control subjects.	—

Secondary

Measure	Time frame
The secondary endpoints of this study are: - the correlation between (1) distribution volume (VT) and binding potential (BP) as quantitative endpoints and (2) the uptake, expressed as SUV, in selected brain regions. This is to determine the best time point for short static scanning as an alternative for extensive dynamic scanning and confirm previous literature findings. - The percentage change in mean SUV between test and retest to assess test-retest variability. - Neuropsychological assessment	—

Measure

Time frame

The secondary endpoints of this study are: - the correlation between (1) distribution volume (VT) and binding potential (BP) as quantitative endpoints and (2) the uptake, expressed as SUV, in selected brain regions. This is to determine the best time point for short static scanning as an alternative for extensive dynamic scanning and confirm previous literature findings. - The percentage change in mean SUV between test and retest to assess test-retest variability. - Neuropsychological assessment

—

Countries

Netherlands

Outcome results